Grandview Asset Management LLC Takes Position in ABIOMED, Inc. (ABMD)

Share on StockTwits

Grandview Asset Management LLC bought a new position in ABIOMED, Inc. (NASDAQ:ABMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 5,837 shares of the medical equipment provider’s stock, valued at approximately $1,897,000. ABIOMED comprises about 2.0% of Grandview Asset Management LLC’s holdings, making the stock its 15th biggest position.

A number of other large investors have also modified their holdings of ABMD. State of Alaska Department of Revenue grew its stake in shares of ABIOMED by 4.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 7,184 shares of the medical equipment provider’s stock valued at $3,230,000 after acquiring an additional 304 shares during the period. Creative Planning grew its stake in shares of ABIOMED by 5.3% during the 3rd quarter. Creative Planning now owns 10,593 shares of the medical equipment provider’s stock valued at $4,764,000 after acquiring an additional 533 shares during the period. Robeco Institutional Asset Management B.V. grew its stake in shares of ABIOMED by 156.9% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 72,160 shares of the medical equipment provider’s stock valued at $31,308,000 after acquiring an additional 44,074 shares during the period. MetLife Investment Advisors LLC grew its stake in shares of ABIOMED by 4.9% during the 3rd quarter. MetLife Investment Advisors LLC now owns 13,052 shares of the medical equipment provider’s stock valued at $5,870,000 after acquiring an additional 613 shares during the period. Finally, Financial Partners Group Inc grew its stake in shares of ABIOMED by 21.1% during the 3rd quarter. Financial Partners Group Inc now owns 3,165 shares of the medical equipment provider’s stock valued at $1,423,000 after acquiring an additional 552 shares during the period. 95.25% of the stock is owned by institutional investors and hedge funds.

In other ABIOMED news, COO David M. Weber sold 24,000 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $351.47, for a total value of $8,435,280.00. Following the completion of the transaction, the chief operating officer now directly owns 161,842 shares in the company, valued at approximately $56,882,607.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin P. Sutter sold 5,985 shares of the company’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total value of $2,091,697.65. Following the completion of the transaction, the director now owns 212,943 shares of the company’s stock, valued at $74,421,449.07. The disclosure for this sale can be found here. Insiders sold a total of 49,928 shares of company stock valued at $17,512,612 over the last 90 days. 3.50% of the stock is currently owned by corporate insiders.

ABMD stock opened at $341.21 on Monday. ABIOMED, Inc. has a 1-year low of $219.13 and a 1-year high of $459.75. The company has a market capitalization of $15.39 billion, a price-to-earnings ratio of 139.27, a price-to-earnings-growth ratio of 3.41 and a beta of 0.38.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.03. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. The business had revenue of $200.56 million during the quarter, compared to the consensus estimate of $200.60 million. On average, equities analysts anticipate that ABIOMED, Inc. will post 3.61 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 price objective for the company in a research note on Friday, January 18th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Friday, December 28th. BTIG Research upgraded ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective for the company in a research note on Friday, November 2nd. Morgan Stanley dropped their price target on ABIOMED from $496.00 to $461.00 and set an “overweight” rating for the company in a research note on Wednesday, January 2nd. Finally, ValuEngine downgraded ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Nine investment analysts have rated the stock with a buy rating, ABIOMED currently has an average rating of “Buy” and an average price target of $413.71.

TRADEMARK VIOLATION WARNING: “Grandview Asset Management LLC Takes Position in ABIOMED, Inc. (ABMD)” was reported by Week Herald and is owned by of Week Herald. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://weekherald.com/2019/02/11/grandview-asset-management-llc-takes-position-in-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: Stochastic Momentum Index (SMI)

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply